Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × palbociclib × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 12 Ovarian Neoplasms 4 Neoplasms 3 Neoplasm Metastasis 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Endometrial Neoplasms 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms by Site 1 Malignant Female Reproductive System Neoplasm 1 Lymphoma, Mantle-Cell 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 ER+ HER2- Advanced Breast Cancer 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Breast Diseases 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡